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Left ventricular hypertrophy [LVH] is defined on a normative
basis; based on 2 standard deviations above the mean left ventric-
ular mass [LVM] in the general population or based on the healthy
population without obesity or hypertension. LVH confers an
increased risk of cardiovascular and all-cause mortality in the gen-
eral population.1,2
Obesity is reaching an epidemic scale worldwide. Obesity car-
diomyopathy is defined as myocardial disease in obese individuals
that cannot be explained by diabetes mellitus, hypertension, coro-
nary artery disease or other etiologies, the presentation of this con-
dition varies from asymptomatic left ventricular dysfunction to
overt dilated cardiomyopathy. LV remodeling, increased LVM,
LVH, and LV dilatation are among the documented cardiac changes
in obese individuals.3–5
Known mechanisms to explain obesity cardiomyopathy
include: increased preload and afterload in response to the high
metabolic activity of adipose tissue, lipotoxicity in the form of fatty
acids and triglycerides accumulation in parenchymal myocytes,
hyperleptinemia, hypoadiponectinemia, and proinflammatory
state.5
Insulin resistance and associated hyperinsulinemia are key
players in this condition through 4 mechanisms: insulin binding
to myocardial IGF-1 receptors inducing LVH, activation of RAAS
with angiotensin II exerting a proliferative hypertrophic action,
activation of SNS leading to induction of cardiac fetal program,
and finally endothelial dysfunction leading to failure to recruit to
myocardial microcirculation in response to stress.5
Blood pressure is considered the most important hemodynamic
factor in the development and extent of left ventricular hypertro-
phy. Hypertensive left ventricular hypertrophy is associated with
a threefold increase in cardiovascular morbidity and mortality. A
powerful relation between LV mass and risk of cardiovascular dis-
ease in subjects with uncomplicated untreated essential hyperten-
sion, even below the upper normal limits of LV mass values. Asignificant relationship continues to exist between left ventricular
mass and blood pressure in hypertensives even under treatment.6,7
A relation between LVH, LVMI, and parathormone [PTH] has
been demonstrated in clinical and experimental studies. PTH was
found to be associated with LVMI in several disease populations
including primary hyperparathyroidism, end stage renal disease
with secondary hyperparathyroidism, essential hypertension, and
patients after aortic valve replacement. The relation between PTH
and LVH was not only shown in disease states, but also for general
population and elderly population.8–16
Possible mechanisms mediating ventricular hypertrophic effect
of PTH can be divided into direct and indirect. Indirectly, high PTH
has been shown to be associated with high BMI, systolic, diastolic,
and central blood pressures, all are established risk factors for
LVH.8,17
Direct mechanisms include: A positive chronotropic action,
intact PTH 1–84 with 3 folds greater potency compared to PTH
1–39, stimulates adenylate cyclase leading to increased intracellu-
lar cyclic AMP which will activate cardiac L-type Ca2+ channels
leading to increased L-type Ca2+ currents with increased intracellu-
lar Ca influx.18
Increase sinoatrial node automaticity by increasing pace maker
currents in SAN.17 A positive inotropic action, through increasing
both heart rate, and coronary blood flow.17 A direct hypertrophic
effect, via activation of protein kinase C and mediated by the func-
tional domain [28–34] e.g. PTH 1–34 or PTH 28–48, through
increasing collagen synthesis, increased cellular protein mass, re-
expression of fetal proteins like creatine kinase BB.18
The aim of this work was to study the role of PTH as a determi-
nant of LV mass in hypertensive and/or obese patients.2. Subjects
The study included 85 subjects of both male and female gender
with age between 20 and 50 years. They were classified into 3
groups, group I: 30 obese hypertensive patients, group II: 30 obese
non-hypertensive patients, attending the Internal Medicine and
the Endocrinology Outpatient Clinics in Alexandria Main Univer-
sity Hospital, and group III: 25 healthy matched subjects that
served as a control group.
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protocol of the study, and all study participants provided a written
informed consent after being explained the nature and aim of the
study.
Exclusion criteria: subjects with cardiac disease (coronary
artery disease, rheumatic heart disease), diabetes mellitus (fasting
plasma glucose 126 mg/dl or the use of antidiabetic drugs), left
ventricular systolic dysfunction (EF < 40%), renal diseases, hepatic
diseases, other endocrinal dysfunction, receiving anti-hypertensive
drugs affecting renin angiotensin aldosterone system were
excluded. e.g. angiotensin converting enzyme inhibitors, angioten-
sin receptor blockers and aldosterone receptor antagonists.3. Methods
All patients were subjected to the following:
Complete physical examination was performed, including blood
pressure measurement. Height, weight, and waist and hip circum-
ferences were measured and BMI was calculated using the formula
[weight in kg/height in m2].
Body fat mass percentage was calculated using the Deurenberg
equation as follows: [body fat percentage = 1.2  BMI + 0.23  age
 10.8  sex  5.4], with age being in years and sex being desig-
nated as 1 for male and 0 for female patients.193.1. Biochemical assays
venous sampling was carried out in the morning (8.00–10.00 a.
m.) after an overnight fast of 8–10 h. The blood was drawn into an
empty tube and then centrifuged for 10 min. The separated serum
was used for the following assays: fasting plasma glucose level,
lipid profile (triglycerides, cholesterol, HDL-C and LDL-C), renal
function tests: serum creatinine and blood urea, total calcium,
and phosphorus. Serum parathormone level was also measured
by using radioimmunoassay method [ DIAsource hPTH-120 min-
IRMA Kit, DIAsource ImmunoAssays S.A., Belgium].203.2. Echocardiography
echocardiographic imaging was performed using HD11XE echo
machine (Philips, USA). Cardiac dimensions and wall thicknesses
were measured according to standard recommendations. Left
ventricular mass was calculated by the following formula: LVM
(Penn) = 1.04[(LVIDD + PWTD + IVSTD)3  LVIDD3]  13.6 g and
was indexed to body surface area using the Dubois formula
[BSA = 0.007184  H0.725 W0.425]. Left ventricular ejection
fraction (LVEF) and left ventricular fractional shortening were
estimated. Left ventricular diastolic function was assessed by mea-
suring mitral flow E wave, A wave, E/A ratio, and mitral annulus
tissue velocities.213.3. Statistical analysis of the data
Data were fed to the computer and analyzed using IBM SPSS
software package version 20.0, Armonk, NY: IBM Corp. Comparison
between different groups regarding categorical variables was
tested using Chi-square test. When more than 20% of the cells have
expected count less than 5, correction for chi-square was con-
ducted using Fisher’s exact test or Monte Carlo correction. The dis-
tributions of quantitative variables were tested for normality. For
normally distributed data, comparison between more than two
populations were analyzed using F-test (ANOVA) and Post Hoc test
(Scheffe). For abnormally distributed data, Kruskal Wallis test was
used to compare between different groups and pair wise compar-ison was assessed using Mann-Whitney test. Significance of the
obtained results was judged at the 5% level.4. Results
All studied groups were matched for age and sex. A significant
increase in BMI, waist circumference, hip circumference, and body
fat percentage was detected among obese patients with or without
hypertension in relation to normal individuals [P = <.001 for all 4
parameters in both groups I, and II versus control group] [Table 1].
There were statistically significantly higher levels of serum PTH
in group I and group II compared to group III [P = .005, .044 respec-
tively]. Higher levels were found in group I compared to group II
but it did not reach statistical significance [P = .287] [Table 1].
There was no statistically significant difference in serum cal-
cium among the three studied groups [Table 1], there was no sig-
nificant correlation between serum PTH and serum calcium.
LVMI was significantly higher in both group I and group II in
comparison to healthy subjects [P = <.001, <.001 respectively].
It was also significantly elevated in group I versus group II
[P = <.001] [Table 1].
A significant positive correlation was found between serum PTH
and left ventricular mass index in the three studied groups
[P = <.001, <.001, .005 for groups I, II, and III respectively] [Fig. 1].
E/A ratio was significantly lower in group I in comparison to
group III [P = .006]. There was no significant difference in MPAP
(mean pulmonary arterial pressure) between the three groups. Left
atrial diameter was significantly higher in obese subjects (group I
and II) compared to healthy control [P = .003, <.001 respectively].
Left atrial volume was significantly higher in group I and group II
compared to group III [P = .008, <.001 respectively] [Table 1].5. Discussion
The aim of this work was to study the role of PTH as a determi-
nant of LV mass in hypertensive and/or obese patients. Our results
revealed significantly higher levels of serum PTH along with signif-
icantly higher LVMI in both group I and group II in comparison to
healthy subjects. A significant positive correlation was found
between serum PTH and left ventricular mass index in the three
studied groups. This correlation is independent of Ca2+ and blood
pressure as there was no statistically significant difference in
serum calcium among the three studied groups, and there was
no significant correlation between serum PTH and serum calcium
or BP.
In 36 untreated patients with mild to moderate essential hyper-
tension, there was a very significant correlation between LVMI and
PTH (p = .00001) even after adjustment for mean 24-h systolic and
diastolic BPs [p = .00001, p = .00003 respectively]. No significant
correlations could be found among office systolic and diastolic
BPs and PTH, however, there was a significant correlation between
mean ambulatory diastolic BP and PTH (p = .020). Similar to our
findings, there was neither correlation between parathyroid hor-
mone and calcium nor between calcium and LV mass index.11
Furthermore, there was no significant correlation between
office systolic and diastolic BPs and LVMI, however, a significant
correlation existed between mean ambulatory systolic BP, mean
ambulatory diastolic BP, and LVMI (p = .026, p = .004
respectively).11
In Another study including 62 essential hypertension patients
and 20 normotensive healthy subjects, when classified as hyper-
tensive versus control, PTH was significantly higher in the essential
hypertension group (p < .001). when classified as those with LVH
[LVMI > 125 g/m2 in men, and >120 g/m2 in women] versus those
without, PTH was significantly higher in those with LVH (p <
Table 1
Anthropometric, Clinical, Biochemical, and Echocardiographic data of the three studied groups.
Parameter Group I (n = 30) Group II (n = 30) Group III (n = 25) p
Age (years) 35.5 ± 8.01 33.17 ± 8.97 32.28 ± 7.40 .318
Male 5(16.7%) 11(36.7%) 9(36%) .163
Female 25(83.3%) 19(63.3%) 16(64%)
Systolic 141.67 ± 14.16 117.33 ± 10.48 116.0 ± 5.77 <.001
p1 < .001*, p2 < .001*, p3 = .654
Diastolic 88.33 ± 7.91 76.67 ± 8.44 76.40 ± 4.90 <.001
p1 < .001*, p2 < .001*, p3 = .894
BMI 48.32 ± 7.98 46.41 ± 11.50 23.64 ± 0.85 <.001
p1 = .378, p2 < .001*, p3 < .001*
Waist circumference (cm) 125.70 ± 17.43 121.10 ± 18.79 88.84 ± 4.60 <.001
p1 = .252, p2 < .001*, p3 < .001*
HIP circumference (cm) 135.77 ± 19.04 132.33 ± 22.56 100.92 ± 9.24 <.001
p1 = .468, p2 < .001*, p3 < .001*
Body fat (%) 58.08 ± 10.31 53.94 ± 15.98 28.95 ± 6.21 <.001
p1 = .177, p2 < .001*, p3 < .001*
Calcium (mg/dl) 8.81 ± 0.30 8.89 ± 0.35 8.77 ± 0.37 .394
Phosphorus (mg/dl) 3.49 ± 0.36 3.83 ± 0.41 3.56 ± 0.41 .003
p1 = .001*, p2 = .493, p3 = .014*
Serum PTH (pg/ml) 29.41 ± 19.44 23.44 ± 15.54 15.85 ± 10.38 .014
p1 = .287, p2 = .005*, p3 = .044*
LVEF (%) 67.23 ± 6.66 70.60 ± 6.95 68.12 ± 5.26 .116
LVMI (gm/m2) 123.72 ± 49.32 87.03 ± 30.4 60.9 ± 8.9 <.001
p1 < .001*, p2 < .001*, p3 < .001*
E/A ratio 1.12 ± 0.53 1.27 ± 0.30 1.40 ± 0.10 .023
p1 = .128, p2 = .006*, p3 = .184
LAD (mm) 33.38 ± 4.36 33.98 ± 2.64 30.20 ± 4.27 .001
p1 = .542, p2 = .003*, p3 < .001*
LAV (ml/m2) 39.89 ± 11.01 44.35 ± 7.34 33.64 ± 5.66 <.001
p1 = .044*, p2 = .008*, p3 < .001*
p: p values comparing between the three groups.
p1: p value for comparing between group I and group II.
p2: p value for comparing between group I and group III.
p3: p value for comparing between group II and group III.
* Statistically significant at p  .05.
Fig. 1. Correlation between serum PTH and left ventricular mass index in the three studied groups
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PTH (p < .0025).12
Recently, Helvacı et al. in a study that included Twenty-seven
newly diagnosed hypertension patients, and 20 healthy individuals
as control, they found that PTH level was significantly higher in the
hypertensive group (p = .006). They also found A significant corre-
lation between LVMI and PTH level in the hypertensive group
(p = .001). There were no correlations between LVMI, and ambula-
tory BP, neither between PTH and BP.13It has been suggested that the higher levels of PTH in essential
hypertension patients may be due to high levels of serum sodium
in patients with essential hypertension, which may be related to
excessive dietary salt intake or a defect in the excretion of sodium,
which leads to excessive urinary calcium excretion, PTH release
increases to compensate for this hypernatremia induced
calciuresis.13
To the best of our knowledge, our study is the first to show a
significant association between PTH and LVMI in obese subjects
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related secondary hyperparathyroidism as a novel mechanism to
explain obesity cardiomyopathy.
High PTH [secondary hyperparathyroidism] is well documented
in obese individuals with a prevalence ranging from 21% in obese
individuals not requiring bariatric surgery to 53% in morbidly
obese patients requiring bariatric surgery. Weight was the main
determinant of increased PTH in morbid obesity and it decreases
significantly with weight loss. Obesity related secondary hyper-
parathyroidism is independent from 25 OH D3, Ca+2, and renal
function. A plausible mechanism may be a direct effect of adipoki-
nes, namely leptin, on PTH secretion as leptin has been shown to be
a PTH secretagogue.22–24
In 2040 general population cohort of healthy subjects without
established cardiovascular disease and not taking antihypertensive
drugs, PTH was a significant predictor of LVMI in males and
females, older and younger than 60 years of age, respectively
[P < .01, <.05]. It was also observed that serum PTH values in the
upper normal range were associated with 14% higher LVMI com-
pared to values in the lower normal range, and the difference
was significant in both sexes. Finally, serum PTH was significantly
higher in men with LVH compared with the rest of the cohort
(P < .01).15
Limitations of this study include lack of ambulatory BP
measurement that showed better correlation to PTH than office
BP in one study. Another limitation was lack of vitamin D status
determination; however, it has been shown that obesity related
secondary hyperparathyroidism is independent from vitamin D
status.11,23
In conclusion, PTH is strongly related to LVMI in obese patients
with or without hypertension as well as normal individuals, inde-
pendent of Ca2+ and blood pressure. To the best of our knowledge,
our study is the first to suggest obesity related secondary
hyperparathyroidism as a novel mechanism to explain obesity
cardiomyopathy.
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